Cited 0 times in
Exploratory biomarker analysis from neoadjuvant atezolizumab, pertuzumab, trastuzumab plus docetaxel (NEO-PATH) in HER2+ early breast cancer
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.